Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI

Brain Research

Volumn 739, Issue 1-2, 1996, Pages 36-45

  Yenari, Midori A ^a   Palmer, James T ^a   Sun, Guo Hua ^a   De Crespigny, Alexander ^a,b   Moseley, Michael E ^a,b   Steinberg, Gary K ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

conopeptide; calcium channel; diffusion weighted MRI; excitotoxicity; focal cerebral ischemia; rat; SNX 111

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; EXCITOTOXIN; NEUROPROTECTIVE AGENT; OMEGA CONOTOXIN MVIIA; PHENYLEPHRINE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CEREBRAL INFARCTION; DATA INTERPRETATION, STATISTICAL; DIFFUSION; DISEASE MODELS, ANIMAL; IMAGE PROCESSING, COMPUTER-ASSISTED; ISCHEMIC ATTACK, TRANSIENT; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; NEUROPROTECTIVE AGENTS; OMEGA-CONOTOXINS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0030580427     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00808-6     Document Type: Article

References (54)

1. [1] The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke, Stroke, 23 (1992) 3-8.
2. [2] Back, T., Hoehn-Berlage, M., Kohno, K. and Hossmann, K.A., Diffusion nuclear magnetic resonance imaging in experimental stroke. Correlation with cerebral metabolites, Stroke, 25 (1994) 494-500.
3. [3] Barone, F., Lysko, P., Price, W., Feuerstein, G., Al-Baracanji, K., Benham, C., Harrison, D., M.H., Bailey, S. and Hunter A., SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice, Stroke, 26 (1995) 1683-1690.
4. [4] Bederson, J.B., Pitts, L.H., Germano, S.M., Nishimura, M.C., Davis, R.L. and Bartkowski, H.M., Evaluation of 2,3,5-tri-phenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats, Stroke, 17 (1986) 1304-1308.
5. [5] Bowersox, S.S. and Luther, R.R., SNX-111, Drugs of the Future, 19 (1994) 128-130.
6. 2+-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia, J. Cereb. Blood Flow Metab., 14 (1994) 903-910.
7. [7] Chen, H., Chopp, M., Zhang, Z.G. and Garcia, J.H., The effect of hypothermia on transient middle cerebral artery occlusion in the rat, J. Cereb. Blood Flow Metab., 12 (1992) 621-628.
8. [8] Choi, D.W., Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage, Trends Neurosci., 11 (1988) 465-469.
9. [9] Choi, D.W., Koh, J.Y. and Peters, S., Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists, J. Neurosci., 8 (1988) 185-196.
10. [10] Choi, D.W., Maulucci-Gedde, M. and Kriegstein, A.R., Glutamate neurotoxicity in cortical cell culture, J. Neurosci., 7 (1987) 357-368.
11. [11] Dardzinski, B.J., Sotak, C.H., Fisher, M., Hasegawa, Y., Li, L. and Minematsu, K., Apparent diffusion coefficient mapping of experimental focal cerebral ischemia using diffusion-weighted echo-planar imaging, Magn. Reson. Med., 30 (1993) 318-325.
12. [12] Gaur, S., Newcomb, R., Rivnay, B., Bell, J.R., Yamashiro, D., Ramachandran, J. and Miljanich, G.P., Calcium channel antagonist peptides define several components of transmitter release in the hippocampus, Neuropharmacology, 33 (1994) 1211-1219.
13. [13] Gelmers, H.J., Gorter, K., de Weerdt, C.J. and Wiezer, H.J., A controlled trial of nimodipine in acute ischemic stroke, N. Engl. J. Med., 318 (1988) 203-207.
14. [14] Grotta, J.C., Pettigrew, L.C., Rosenbaum, D., Reid, C., Rhoades, H. and McCandless, D., Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats, Stroke, 19 (1988) 447-454.
15. [15] Hara, H., Nagasawa, H. and Kogure, K., Nimodipine prevents postischemic brain damage in the early phase of focal cerebral ischemia, Stroke, 21 (1990) IV102-104.
16. 45Ca accumulation, Acta Neurochir. Suppl., 60 (1994) 521-523.
17. [17] Jacewicz, M., Brint, S., Tanabe, J., Wang, X.J. and Pulsinelli, W.A., Nimodipine pretreatment improves cerebral blood flow and reduces brain edema in conscious rats subjected to focal cerebral ischemia, J. Cereb. Blood Flow Metab., 10 (1990) 903-913.
18. [18] Kimura, H., Hamasaki, N., Yamamoto, M. and Tomonaga, M., Circulation of red blood cells having high levels of 2,3-bisphosphoglycerate protects rat brain from ischemic metabolic changes during hemodilution, Stroke, 26 (1995) 1431-1436.
19. [19] Knight, R.A., Dereski, M.O., Helpern, J.A., Ordidge, R.J. and Chopp, M., Magnetic resonance imaging assessment of evolving focal cerebral ischemia. Comparison with histopathology in rats, Stroke, 25 (1994) 1252-1261.
20. [20] Kunis, D., Perez-Pinzon, M., Sun, G. and Steinberg, G., SNX-111, a novel N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits, Soc. Neurosci. Abstr., 20 (1994) 184.
21. [21] Liszczak, T.M., Hedley-Whyte, E.T., Adams, J.F., Han, D.H., Kolluri, V.S., Vacanti, F.X., Heros, R.C. and Zervas, N.T., Limitations of tetrazolium salts in delineating infarcted brain, Acta Neuropathol. (Berl.), 65 (1984) 150-157.
22. [22] Lo, E.H., Matsumoto, K., Pierce, A.R., Garrido, L. and Luttinger, D., Pharmacologic reversal of acute changes in diffusion-weighted magnetic resonance imaging in focal cerebral ischemia, J. Cereb. Blood Flow Metab., 14 (1994) 597-603.
23. [23] Longa, E.Z., Weinstein, P.R., Carlson, S. and Cummins, R., Reversible middle cerebral artery occlusion without craniectomy in rats, Stroke, 20 (1989) 84-91.
24. [24] Mattson, M.P., Calcium and neuronal injury in Alzheimer's disease. Contributions of β-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise, Ann. NY Acad. Sci., 747 (1994) 50-76.
25. [25] McCleskey, E.W., Fox, A.P., Feldman, D.H., Cruz, L.J., Olivera, B.M., Tsien, R.W. and Yoshikami, D., ω-Conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle, Proc. Natl. Acad. Sci. USA, 84 (1987) 4327-4331.
26. [26] McCulloch, J., Ozyurt, E., Park, C.K., Nehls, D.G., Teasdale, G.M. and Graham, D.I., Glutamate receptor antagonists in experimental focal cerebral ischaemia, Acta Neurochir. Suppl., 57 (1993) 73-79.
27. [27] Miller, R.J., Multiple calcium channels and neuronal function, Science, 235 (1987) 46-52.
28. [28] Minematsu, K., Fisher, M., Li, L. and Sotak, C.H., Diffusion and perfusion magnetic resonance imaging studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats, Stroke, 24 (1993) 2074-2081.
29. [29] Minematsu, K., Li, L., Fisher, M., Sotak, C.H., Davis, M.A. and Fiandaca, M.S., Diffusion-weighted magnetic resonance imaging: rapid and quantitative detection of focal brain ischemia, Neurology, 42 (1992) 235-240.
30. [30] Minematsu, K., Li, L., Sotak, C.H., Davis, M.A. and Fisher, M., Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rats, Stroke, 23 (1992) 1304-1310.
31. [31] Mintorovitch, J., Moseley, M.E., Chileuitt, L., Shimizu, H., Cohen, Y. and Weinstein, P.R., Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats, Magn. Reson. Med., 18 (1991) 39-50.
32. [32] Moseley, M.E., Cohen, Y., Mintorovitch, J., Chileuitt, L., Shimizu, H., Kucharczyk, J., Wendland, M.F. and Weinstein, P.R., Early detection of regional cerebral ischemia in cats: comparison of diffusion-and T2-weighted MRI and spectroscopy, Magn. Reson. Med., 14 (1990) 330-346.
33. [33] Moseley, M.E., Kucharczyk, J., Mintorovitch, J., Cohen, Y., Kurhanewicz, J., Derugin, N., Asgari, H. and Norman, D., Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats, Am. J. Neuroradiol., 11 (1990) 423-429.
34. [34] Mossakowski, M.J. and Gadamski, R., Nimodipine prevents delayed neuronal death of sector CA1 pyramidal cells in short-term forebrain ischemia in Mongolian gerbils, Stroke, 21 (1990) IV120-122.
35. [35] Muller, T.B., Haraldseth, O., Jones, R.A., Sebastiani, G., Godtliebsen, F., Lindboe, C.F. and Unsgard, G., Combined perfusion and diffusion-weighted magnetic resonance imaging in a rat model of reversible middle cerebral artery occlusion, Stroke, 26 (1995) 451-457.
36. [36] Muller, T.B., Haraldseth, O., Jones, R.A., Sebastiani, G., Lindboe, C.F., Unsgard, G. and Oksendal, A.N., Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model, Stroke, 26 (1995) 1453-1458.
37. [37] Newcomb, R. and Palma, A., Effects of diverse ω-conopeptides on the in vivo release of glutamic and γ-aminobutyric acids, Brain Res., 638 (1994) 95-102.
38. [38] Olivera, B.M., Cruz, L.J., de Santos, V., LeCheminant, G.W., Griffin, D., Zeikus, R., McIntosh, J.M., Galyean, R., Varga, J., Gray, W.R. et al., Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using ω-conotoxin from Conus magus venom, Biochemistry, 26 (1987) 2086-2090.
39. [39] Olivera, B.M., Gray, W.R., Zeikus, R., McIntosh, J.M., Varga, J., Rivier, J., de Santos, V. and Cruz, L.J., Peptide neurotoxins from fish-hunting cone snails, Science, 230 (1985) 1338-1343.
40. [40] Olivera, B.M., Rivier, J., Clark, C., Ramilo, C.A., Corpuz, G.P., Abogadie, F.C., Mena, E.E., Woodward, S.R., Hillyard, D.R. and Cruz, L.J., Diversity of Conus neuropeptides, Science, 249 (1990) 257-263.
41. [41] Palmer, J., Yenari, M., Sun, G.H., de Crespigny, A., Moseley, M. and Steinberg, G., SNX-111 in a rat model of transient focal cerebral ischemia using diffusion MRI, Soc. Neurosci Abstr., 21 (1995) 216.
42. [42] Park, C.K., Mendelow, A.D., Graham, D.I., McCulloch, J. and Teasdale, G.M., Correlation of triphenyltetrazolium chloride perfusion staining with conventional neurohistology in the detection of early brain ischaemia, Neuropathol. Appl. Neurobiol., 14 (1988) 289-298.
43. [43] Perez-Pinzon, M., Kunis, D., Sun, G. and Steinberg, G., SNX-111 in a rabbit model of focal ischemia, J. Neurosurg., (1996) (manuscript submitted).
44. [44] Sauter, A. and Rudin, M., Calcium antagonists for reduction of brain damage in stroke, J. Cardiovasc. Pharmacol., 15 (1990) S43-S47.
45. [45] Simon, R.P., Swan, J.H., Griffiths, T. and Meldrum, B.S., Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain, Science, 226 (1984) 850-852.
46. [46] Smith, M.-L. and Siesjo, B.K., Postischemia treatment with the ω-conopeptide SNX-111 protects the rat brain against ischemic damage. In J. Krieglstein and H. Oberpilcher (Eds.), Pharmacology of Cerebral Ischemia, Wissenschaftliche Verlagsgesellshft, Stuttgart, Germany, 1992, pp. 161-167.
47. [47] Steinberg, G.K., George, C.P., DeLaPaz, R., Shibata, D.K. and Gross, T., Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits, Stroke, 19 (1988) 1112-1118.
48. [48] Steinberg, G.K., Perez-Pinzon, M.A., Sun, G.H. and Kunis, D.M., A novel N-type calcium channel antagonist, SNX-111, protects against focal cerebral ischemia, J. Cereb. Blood Flow Metab., 15 (1995) S385.
49. [49] Takizawa, S., Matsushima, K., Fujita, H., Nanri, K., Ogawa, S. and Shinohara, Y., A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia, J. Cereb. Blood Flow Metab., 15 (1995) 611-618.
50. [50] Tsien, R.W., Lipscombe, D., Madison, D.V., Bley, K.R. and Fox, A.P., Multiple types of neuronal calcium channels and their selective modulation, Trends Neurosci., 11 (1988) 431-438.
51. [51] Valentino, K., Newcomb, R., Gadbois, T., Singh, T., Bowersox, S., Bitner, S., Justice, A., Yamashiro, D., Hoffman, B.B., Ciaranello, R., Miljanich, G. and Ramachandran, J., A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia, Proc. Natl. Acad. Sci. USA, 90 (1993) 7894-7897.
52. [52] Yenari, M.A., Palmer, J.T., Sun, G.H., de Crespigny, A. and Moseley, M.E., Diffusion-weighted MRI demonstrates early improvement following treatment with SNX-111, a selective N-type calcium channel blocker, in a rodent model of transient focal cerebral ischemia, Neurology, 46 (1996) A195.
53. [53] Zhang, R.L., Chopp, M., Chen, H., Garcia, J.H. and Zhang, Z.G., Postischemic (1 hour) hypothermia significantly reduces ischemic cell damage in rats subjected to 2 hours of middle cerebral artery occlusion, Stroke, 24 (1993) 1235-1240.
54. [54] Zhao, Q., Smith, M.L. and Siesjo, B.K., The ω-conopeptide SNX-111, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia, Acta Physiol. Scand., 150 (1994) 459-461.